Literature DB >> 11064390

Changes of expression level of the differentiation markers in papillary thyroid carcinoma under thyrotropin suppression therapy in vivo immunohistochemical detection of thyroglobulin, thyroid peroxidase, and thyrotropin receptor.

K Tanaka1, H Sonoo, Y Yamamoto, K Udagawa, H Kunisue, I Arime, S Yamamoto, J Kurebayashi, K Shimozuma.   

Abstract

BACKGROUND AND OBJECTIVES: Differences in the expression levels of Thyroglobulin (Tg), Thyroid peroxidase (TPO) and thyrotropin receptor (TSH-R) in primary and recurrent specimens under a suppressive serum TSH condition were elucidated in 26 papillary carcinoma patients.
METHODS: Immunohistochemical detection was performed by use of each monoclonal antibody against Tg, TPO, and TSH-R. The staining concentrations of the three markers in each specimen were measured for comparison.
RESULTS: The mean staining concentrations of Tg, TPO, and TSH-R in the entire primary tumor were 103.92, 104.6 and 89.25, respectively. Five cases showed stronger expression of all the differentiation markers and eight cases showed weaker expression of all these markers in recurrent tissue than in primary tumors. The weaker expression of TSH-R at the recurrent site as compared with that at the primary site significantly demonstrated the shortness of the disease free interval or overall survival. There were significant differences between the death due to cancer and the weaker expression of TSH-R in the recurrent tumor as compared with that in the primary tumor.
CONCLUSIONS: Under the TSH suppressive condition, the markers were not expressed uniformly among recurrent tumors. Even under that state, however, low expression of TSH-R in the recurrent tissue was strongly related to a poorer outcome in the patients. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11064390     DOI: 10.1002/1096-9098(200010)75:2<108::aid-jso7>3.0.co;2-v

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  5 in total

1.  Preoperative determination of serum thyroglobulin to identify patients with differentiated thyroid cancer who may present recurrence without increased thyroglobulin.

Authors:  B Gibelli; P Tredici; C De Cicco; L Bodei; M T Sandri; G Renne; R Bruschini; N Tradati
Journal:  Acta Otorhinolaryngol Ital       Date:  2005-04       Impact factor: 2.124

2.  Functional thyrotropin receptor attenuates malignant phenotype of follicular thyroid cancer cells.

Authors:  S Hoffmann; K Maschuw; I Hassan; A Wunderlich; S Lingelbach; A Ramaswamy; L C Hofbauer; A Zielke
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

3.  Current trends in TSH suppression therapy for patients with papillary thyroid carcinoma in Japan: results of a questionnaire distributed to councilors of the Japanese Society of Thyroid Surgery.

Authors:  Katsuhiro Tanaka; Hiroshi Sonoo
Journal:  Surg Today       Date:  2011-12-17       Impact factor: 2.549

Review 4.  Autophagy in thyroid cancer: present knowledge and future perspectives.

Authors:  Romana T Netea-Maier; Viola Klück; Theo S Plantinga; Johannes W A Smit
Journal:  Front Endocrinol (Lausanne)       Date:  2015-02-18       Impact factor: 5.555

Review 5.  Thyroid malignant neoplasm-associated biomarkers as targets for oncolytic virotherapy.

Authors:  Mingxu Guan; Yanping Ma; Sahil Rajesh Shah; Gaetano Romano
Journal:  Oncolytic Virother       Date:  2016-06-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.